Case study in disruptive innovation: Restasis and the treatment of dry eye

At OSN New York 2015, Ocular Surgery News held a symposium on disruptive innovations in ophthalmology, discussing new diagnostics, devices and therapeutic treatments that could be considered disruptive. This series will take a look back at disruptive innovations in ophthalmology that took place to examine how and why they were able to change ophthalmic practice.In this installment, OSN spoke with David LeCause, vice president of U.S. eye care sales and marketing at Allergan, about the introduction of Restasis (cyclosporine ophthalmic emulsion 0.05%) as a treatment for dry eye and how that introduction helped drive new innovations in the dry eye market as well as the dry eye center.